


PHARMACEUTICAL 2020

Equillium Inc. Rank 122 of 358





PHARMACEUTICAL 2020

Equillium Inc. Rank 122 of 358

The relative strengths and weaknesses of Equillium Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Equillium Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 123% points. The greatest weakness of Equillium Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 45% points.

The company's Economic Capital Ratio, given in the ranking table, is 134%, being 98% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	55,431
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,883
Liabilities, Non-Current	127
Other Assets	15
Other Compr. Net Income	16
Other Expenses	0
Other Liabilities	9,681
Other Net Income	1,127
Other Revenues	0
Property and Equipment	93
Research and Development	17,640
Selling, General and Administrative Expense	9,087

Output Variable	Value in 1000 USD
Assets	55,539
Liabilities	13,691
Expenses	26,727
Revenues	0
Stockholders Equity	41,848
Net Income	-25,600
Comprehensive Net Income	-25,592
Economic Capital Ratio	134%

